Revvity expands access to base editing technology with aim to accelerate discovery to cure

Waltham, mass.--(business wire)--revvity, inc., (nyse: rvty) today unveils its groundbreaking pin-point™ base editing platform reagents, providing researchers with unparalleled access to implement the advanced gene editing technique in their preclinical laboratories. base editing represents a pivotal advancement in crispr gene editing, providing the capability for complex and safe multi-gene editing, which can result in enhanced functional genomics insights for optimizing drug development, as w.
RVTY Ratings Summary
RVTY Quant Ranking